(R)-(+)-1-(1-Naphthyl)ethylamine CAS 3886-70-2 Purity >99.5% (HPLC) Cinacalcet Hydrochloride Intermediate
Shanghai Ruifu Chemical Co., Ltd. is the leading supplier of (R)-(+)-1-(1-Naphthyl)ethylamine (CAS: 3886-70-2) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available, strong after-sale service. Welcome to order. Please contact: alvin@ruifuchem.com
Chemical Name | (R)-(+)-1-(1-Naphthyl)ethylamine |
Synonyms | (R)-(+)-α-Methyl-1-Naphthalenemethylamine; (R)-(+)-α-(1-Aminoethyl)naphthalene |
CAS Number | 3886-70-2 |
CAT Number | RF-CC309 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C12H13N |
Molecular Weight | 171.24 |
Boiling Point | 80℃/1 mmHg |
Specific Gravity (20/20) | 1.07 |
Refractive Index | N20/D 1.621~1.624 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | Colorless to Light Yellow Oily Liquid |
Purity / Analysis Method | >99.5% (HPLC) |
1-(Naphthalen-2-yl)ethanamine | <0.20% (HPLC) |
(R)-(+)-1-(2-Naphthyl)ethylamine | <0.20% (HPLC) |
1-Acetonaphthone | <0.20% (HPLC) |
Optical Purity | >99.5% (HPLC) |
Specific Rotation | +55.0°±5.0°(C=2, EtOH) |
Water (Karl Fischer) | <0.50% |
Test Standard | Enterprise Standard |
Usage | Intermediate of Cinacalcet Hydrochloride (CAS: 364782-34-3) |
Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
(R)-(+)-1-(1-Naphthyl)ethylamine (CAS: 3886-70-2) is a chiral derivatization reagent, used in chiral synthesis in organic reactions. (R)-(+)-1-(1-Naphthyl)ethylamine is an intermediate of Cinacalcet Hydrochloride (CAS: 364782-34-3). Cinacalcet Hydrochloride is the first entry in a new class of therapeutic agents called the calcimimetics. It was launched as an oral treatment for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis and for hypercalcemia in patients with parathyroid carcinoma. Cinacalcet is a calcium-like agent, which can improve the disorder of bone metabolism in uremia and delay the progression of vascular and valve calcification in dialysis patients. However, long-term use of cinacalcet can also cause side effects such as nausea and vomiting, hypocalcemia, and excessive suppression of parathyroid hormone (PTH). The characteristic of Sinacase is not only to reduce the serum PTH level, but also to reduce the serum calcium, serum phosphorus and serum calcium and phosphorus product levels. It can inhibit the occurrence and progression of cardiovascular diseases caused by ectopic calcification.